Acute Myeloid Leukemia (AML) ในผู้ป่วยสูงอายุ
Keywords:
-Abstract
-
Downloads
References
Ries LAG, Kosary CL, Hankey BF, et al, eds. SEER Cancer Statistics Review, 1973-1994. Bethesda, MD, National Cancer Institute 1997, NIH Pub. No 97-2789.
Taylor POA, Reid MM, Stark AN, et al. De novo acute myeloid leukemia in patients over 55-year-old. A population-based study of incidence, treatment and outcome. Leukemia 1995;9:231.
Brincker H. Estimate of overall treatment results on acute nonlymphocytic leukemia based on age-speciic rates of incidence and of complete remission. Cancer Treat Rep 1985;69:5-11.
Cartwright RA, Staines A. Acute leukemias. Epidemiology of hematological disease - Part I. In: Fleming AT, ed. Bailieries Clin Haematol 1992;5:1-26.
Buchner T, Urbanitz D, Hiddlemann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML). Two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985;3:1583-9.
Rees JHK, Gray RG, Swirsky D, et al. Principal results of the Medical research Council'8th acute myeloid leukemia trial. Lancet 1986;2:1236-41.
Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two post-induction strategies for the treatment of acute non-lymphocytic leukemia: A Cancer and Leukemia Group B Study. *Blood 1987;69:1441-9.
Dillmann RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for
acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B. Blood 1991,78:2520-6.
Vogler WR, Velez-Garcia E, Weiner RS, et al A phase III trial comparing idarubicin and daunorubicin combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study. J Clin Oncol 1992;10:1103-11.
Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherpy in adults with acute myeloid leukemia. N Engl J Med 1994,6,896-902.
Buchner T, Hiddemann W, Loffler H, et al. Treatment of AML in the elderly. Full dose versus reduced dose induction treatment. Blood 1995;86(suppl 1):434a.
Rees JHK, Gray RG, Wheatley K. Dose intensification in acute myeloid leukemia; Greater effectiveness at lower cost - Principal report of the Medical Research Council's AML9 Study. Br J Hematol 1996;94:89-98.
Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997;90:4710-8.
Hiddemann W, Kern W, Schochoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 19999;17:3569-76.
Groves F, Linet M, Devesa S. Epidemiology of leukemia. In: Henderson G, Lister M, Greaves H, eds. Leukemia. 6 ed. Philadelphia: WB Saunders, 1996:152.
Pedersen-Bjergaard J, Philip P, Olesen Larsen S, et al. Therpy-related myelodysplasia and acute myeloid leukernia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen
series. Leukemia 1990;7:1975.
Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-7.
Harousseau JL. Acute myeloid leukemia in the elderly. Blood Rev 1998;12:145-53.
Rowley JD, Alimena G, Garson OM, et al. A collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patient age and karyotype. Blood 1982;59:1013.
Palka G, Calabrese G, Fiortoni G, et al Cytogenetic survey of 80 patients with acute nonlymphocytic leukemia. Cancer Genet Cytogenet 1992:59:45
Fenaux P, Dreudhomme C, Lai JL, et al Cytogenetics and their prognostic value in de novo acute myeloid leukemia: A report on 283 cases. Br J Haematol 1989;73:61.
Lancet JE, Willman CL, Bennett JM. Acute myelogenous leukemia and aging: Clinical interaction. Hemato Onco Clinic North Am 2000;14:251-67.
Chin KV, Pastan I, Gottesman MM. Function and regulation of the human multidrug resistance gene. Adv Cancer Res 1993;60:157.
List AF, Spier CS, Grogan TM, et al. Overexpression of the major vault transporter protein Lung-Resistance Protein predicts treatment outcome in acute myeloid leukemia Blood 1996;87:2464.
Willman CL. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: Studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 1997;34:25
Te Boekhorst PAW, de Leeuw K, Schoester M, et al. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cell. Blood 1993;82:3157.
Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: Assessment of multi-drug resistance (MDRi) and cytogenetics distinguishes biologic subgroups with remarkably distinct response to standard chemotherapy. A Southwest Oncology Group Study. Blood 1997:89:32223.
Borg AG, Burgess R, Green LM, et al. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 1998;103:1083.
Baudard M, Maric JP, Cadiou M, et al. Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients. Br J Haematol 1994;86:82.
Heinemann B, Jehn U. Acute myeloid leukemia in the elderly. Biologic features and search for adequate treatment. Ann Hematol 1991;63:179.
Repetto L, Venturino A, Vercelli M, et al. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer 1998;82:760.
Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 19999;341:1051-62.
Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia. A randomized phase III study of European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989;7:1268-74.
Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myeloid leukemia: A CALGB study. Blood 1982;60:454-62.
Kahn SB, Begg CB, Mazza JJ, et al. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1984;2:865-70.
Buchner T, Hiddlemann W, Loffler H, et al. Double induction strategy in AMI. comparing high with standard dose Ara-C. Hematotoxicity and antleukemic efficacy. Blood 1994;84(suppl 1):232a,
Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Blood 199;75:27- -32.
Tilly H, Casaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990;8:272-9.
Ruutu T, Almqvist A, Hallmann, et al Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients. A randomized comparison with 5-day TAD-Finnish Leukemia Group. Leukemia 1994;8:11-5.
Rowe JM, Andersen JW, Mazza JJ, et al. A randomized, placebo-controlled phase Ill study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogencus leukemia. A study of the Eastern Cooperative Oncology Group (E1490). Blood 1995,86:457-62.
Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colonystimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995;332:1678-83.
Stone RM, Berg DT, Stephen LG, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherpy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995,333332.1671-7.
Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML). Final report of AML-11, a phase III randomized study of the Leukemia Coopeartive Group of Buropean Organization for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 1997;90:2952-61.
Witz F, Sadoun A, Perrin M-C, et al A placebo-controlled study of recombinant human granulocytemacrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 1998;91:2722-30.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
